Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TVFCB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MAb-DMBA-SIL-Dox
|
|||||
| Synonyms |
MAb DMBA SIL DOX
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Thyroid cancer [ICD11:2D10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
5.57
|
|||||
| Structure |
|
|||||
| Antibody Name |
Cetuximab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
DMBA-SIL
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation with the respective EGFR mAb via thiolmaleimide Michael addition.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.